Literature DB >> 25254357

Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.

Gregory Ducrocq1, Phillip J Schulte, Richard C Becker, Christopher P Cannon, Robert A Harrington, Claes Held, Anders Himmelmann, Riitta Lassila, Robert F Storey, Emmanuel Sorbets, Lars Wallentin, Philippe Gabriel Steg.   

Abstract

AIMS: We sought to describe the differential effect of bleeding events in acute coronary syndromes (ACS) on short- and long-term mortality according to their type and severity. METHODS AND
RESULTS: The PLATO trial randomised 18,624 ACS patients to clopidogrel or ticagrelor. Post-randomisation bleeding events were captured according to bleeding type (spontaneous or procedure-related), with PLATO, TIMI, and GUSTO definitions. The association of bleeding events with subsequent short-term (<30 days) and long-term (>30 days) all-cause mortality was assessed using time-dependent Cox proportional hazard models. A model was fitted to compare major and minor bleeding for mortality prediction. Of 18,624 patients, 2,189 (11.8%) had at least one PLATO major bleed (mean follow-up 272.2±123.5 days). Major bleeding was associated with higher short-term mortality (adjusted hazard ratio [HR] 9.28; 95% confidence interval [CI]: 7.50-11.48) but not with long-term mortality (adjusted HR 1.28; 95% CI: 0.93-1.75). Spontaneous bleeding was associated with short-term (adjusted HR 14.59; 95% CI: 11.14-19.11) and long-term (adjusted HR 3.38; 95% CI: 2.26-5.05) mortality. Procedure-related bleeding was associated with short-term mortality (adjusted HR 5.29; 95% CI: 4.06-6.87): CABG-related and non-coronary-procedure-related bleeding were associated with a higher short-term mortality, whereas PCI or angiography-related bleeding was not associated with either short- or long-term mortality. Similar results were obtained using the GUSTO and TIMI bleeding definitions.
CONCLUSIONS: Major bleeding is associated with high subsequent mortality in ACS. However, this association is much stronger in the first 30 days and is strongest for spontaneous (vs. procedure-related) bleeding.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25254357     DOI: 10.4244/EIJY14M09_11

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  15 in total

1.  Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.

Authors:  Charles V Pollack; Farideh Davoudi; Deborah B Diercks; Richard C Becker; Stefan K James; Soo Teik Lim; Phillip J Schulte; Jindrich Spinar; Philippe Gabriel Steg; Robert F Storey; Anders Himmelmann; Lars Wallentin; Christopher P Cannon
Journal:  Clin Cardiol       Date:  2017-06-09       Impact factor: 2.882

2.  One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial.

Authors:  Enrico Fabris; Sinem Kilic; Arnoud W J Van't Hof; Jurrien Ten Berg; Ana Ayesta; Uwe Zeymer; Martial Hamon; Louis Soulat; Debra Bernstein; Prodromos Anthopoulos; Efthymios N Deliargyris; Philippe Gabriel Steg
Journal:  JAMA Cardiol       Date:  2017-07-01       Impact factor: 14.676

Review 3.  Current and future antiplatelet therapies: emphasis on preserving haemostasis.

Authors:  James D McFadyen; Mathieu Schaff; Karlheinz Peter
Journal:  Nat Rev Cardiol       Date:  2018-01-03       Impact factor: 32.419

Review 4.  Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare.

Authors:  Sean Esmonde; Divyesh Sharma; Aaron Peace
Journal:  Cardiovasc Diagn Ther       Date:  2018-10

5.  Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.

Authors:  Eric A Secemsky; Robert W Yeh; Dean J Kereiakes; Donald E Cutlip; David J Cohen; P Gabriel Steg; Christopher P Cannon; Patricia K Apruzzese; Ralph B D'Agostino; Joseph M Massaro; Laura Mauri
Journal:  JAMA Cardiol       Date:  2017-05-01       Impact factor: 14.676

Review 6.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

7.  Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease.

Authors:  Michele Massimo Gulizia; Furio Colivicchi; Maurizio Giuseppe Abrignani; Marco Ambrosetti; Nadia Aspromonte; Gabriella Barile; Roberto Caporale; Giancarlo Casolo; Emilia Chiuini; Andrea Di Lenarda; Pompilio Faggiano; Domenico Gabrielli; Giovanna Geraci; Alessio Gaetano La Manna; Aldo Pietro Maggioni; Alfredo Marchese; Ferdinando Maria Massari; Gian Francesco Mureddu; Giuseppe Musumeci; Federico Nardi; Antonio Vittorio Panno; Roberto Franco Enrico Pedretti; Massimo Piredda; Enrico Pusineri; Carmine Riccio; Roberta Rossini; Fortunato Scotto di Uccio; Stefano Urbinati; Ferdinando Varbella; Giovanni Battista Zito; Leonardo De Luca
Journal:  Eur Heart J Suppl       Date:  2018-05-31       Impact factor: 1.803

8.  Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study.

Authors:  Christoph K Naber; Philip Urban; Paul J Ong; Mariano Valdes-Chavarri; Alexandre A Abizaid; Stuart J Pocock; Franco Fabbiocchi; Christophe Dubois; Samuel Copt; Samantha Greene; Marie-Claude Morice
Journal:  Eur Heart J       Date:  2017-04-01       Impact factor: 29.983

9.  Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis.

Authors:  Yousif Ahmad; Ozan Demir; Christopher Rajkumar; James P Howard; Matthew Shun-Shin; Christopher Cook; Ricardo Petraco; Richard Jabbour; Ahran Arnold; Angela Frame; Nilesh Sutaria; Ben Ariff; Gajen Kanaganayagam; Darrel Francis; Jamil Mayet; Ghada Mikhail; Iqbal Malik; Sayan Sen
Journal:  Open Heart       Date:  2018-01-26

10.  Reversal of Antithrombotic Therapy: Is it Necessary and Sufficient?

Authors:  Richard C Becker
Journal:  JACC Basic Transl Sci       Date:  2017-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.